Sunovion Pharmaceuticals Selects BioPharm Systems' Siebel Clinical Trial Management System Accelerator to Facilitate Fully Outsourced Clinical Trial Management Model
BioPharm Systems, a leading global IT consulting and managed services provider (MSP) specializing in Oracle's clinical trial, data, safety, and pharmacovigilance management systems, today announced that Sunovion Pharmaceuticals Inc. (Sunovion) has selected ASCEND for their clinical trial management system (CTMS). ASCEND is a pre-configured and enhanced version of Siebel Clinical, Oracle's CTMS. The system is configured to meet most organizations' CTMS requirements out-of-the-box, providing smaller organizations with what they need to get started and larger organizations with a robust base for their more complex needs.
For Sunovion, BioPharm Systems will implement ASCEND with minor custom configurations and integrate the system with the company's two preferred contract research organizations' (CROs') CTMS solutions. In addition, Sunovion has elected to host ASCEND in the cloud in BioPharm Systems' state-of-the-art data center.
"We are honored to have Sunovion as one of our newest hosted ASCEND clients," said Param Singh, vice president of clinical trial management solutions, BioPharm Systems. "Together, we have designed an implementation approach that involves rolling releases, which will allow Sunovion to finalize their process documentation, roll out training, and begin using their production system prior to all of the work streams being completed. This is cutting-edge and we are excited to get started."
Despite the complex nature of the project, the final work stream is scheduled to go live this year. Sunovion is planning more integrations with ASCEND over the next three years, including their clinical inventory management system (CIMS), electronic document management system (EDMS), Oracle Health Sciences Clinical Development Analytics (CDA) solution, as well as additional CROs.
BioPharm Systems is a Gold level member of Oracle PartnerNetwork (OPN) and an Oracle Accelerate solution provider. The company has achieved Specializations in Oracle Argus Safety Suite, Oracle Life Sciences Data Hub, and Oracle Accelerate for Midsize Companies.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
